Stocklytics score rationale: value 43, quality 39, growth 52.
Financials
2019
2020
2021
2022
2023
2024
2025
31918000
66616000
36772000
83029000
91434000
489682000
586321000
Alvotech, along with its various subsidiaries, is dedicated to the global development and manufacturing of biosimilar pharmaceuticals. Its product offerings span key therapeutic categories, encompassing autoimmune conditions, eye disorders, bone diseases, and cancer. A flagship program for the company is AVT02, a high-concentration biosimilar equivalent to Humira. This candidate is designed to address a range of…
Forecast
Consensus Buy from 7 analysts. Average price target $8.00, +62.4% versus the current price. Low $8.00. High $8.00.
Analysts have an average 12-month price target of $8.00 for Alvotech (ALVO), 62.4% above the current price of $4.92. Of 7 analysts covering the stock, 6 rate it Buy or Strong Buy, 1 Hold, and 0 Sell or Strong Sell, giving a consensus of Buy.
Forecasts are third-party estimates and often wrong. They are not investment advice.
ALVO price target
12-month price target
Low
$8.00
Average
$8.00
High
$8.00
The average is 62.4% above the current price of $4.92.
Is Alvotech a buy or sell?
Of 7 analysts, 6 rate Alvotech Buy or Strong Buy, 1 Hold, and 0 Sell or Strong Sell. The consensus label is Buy. That split is not a recommendation.
The Stocklytics Score for ALVO is 45 out of 100. It averages value, quality, and growth against a large-cap US universe. It is not a price target and not a buy or sell rating. Fair value is a separate estimate on the fair value tab.
ALVO forecast FAQs
What is the ALVO price target?
$8.00 average, with a published range of $8.00 to $8.00.
Is Alvotech a buy or sell?
The consensus is Buy from 7 analysts. This is not a recommendation.
What is the Alvotech stock forecast for 2026?
Analysts' average EPS estimate for 2026 on file is -0.01. The average revenue estimate is $587.59 million.
What will ALVO be worth in 2030?
No reliable forecast exists that far out.
When is Alvotech's next earnings report?
The next earnings date is shown on the stock page when a future report is on the calendar. This forecast does not invent a date.
Capital is at risk. Stocklytics is operated by Stocklytics Inc., a Marshall Islands company. It is not regulated by the FCA and does not give investment advice.